Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

Annals of the Rheumatic Diseases

Volumn 76, Issue 3, 2017, Pages 504-510

  Strangfeld, A ^a   Richter, A ^a   Siegmund, B ^b   Herzer, P ^c   Rockwitz, K ^d   Demary, W ^d   Aringer, M ^e   Meissner Y ^a   Zink, A ^a,b   Listing, J ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Scientific Advisory Board   (Germany)

^d University Medicine Dresden ^*  (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Corticosteroids; DMARDs (biologic); NSAIDs; Outcomes research

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ABATACEPT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIVERTICULITIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; ABDOMEN, ACUTE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; COMPARATIVE STUDY; GERMANY; INTESTINAL PERFORATION; METABOLISM; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; REGISTER; SIGMOID DISEASES; SINGLE BLIND PROCEDURE;

ABATACEPT; ABDOMEN, ACUTE; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; C-REACTIVE PROTEIN; GERMANY; HUMANS; INCIDENCE; INTESTINAL PERFORATION; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RITUXIMAB; SIGMOID DISEASES; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978805792     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209773     Document Type: Article

References (23)

1. Hart AR, Kennedy HJ, Stebbings WS, et al. How frequently do large bowel diverticula perforate?. An incidence and cross-sectional study. [Article]. Eur J Gastroenterol Hepatol 2000;12:661-5.
2. Morris CR, Harvey IM, Stebbings WSL, et al. Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 2003;90:1267-72.
3. Svenningsen P, Manoharan T, Foss NB, et al. Increased mortality in the elderly after emergency abdominal surgery. Dan Med J 2014;61:A4876.
4. Prior P, Symmons DP, Scott DL, et al. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
5. Henry DA, Johnston A, Dobson A, et al. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. Br Med J (Clin Res Ed) 1987;295:1227-9.
6. Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006;24:751-67.
7. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
8. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 1985;290:347-9.
9. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346-51.
10. Mpofu S, Mpofu CMA, Hutchinson D, et al. Steroids, non-steroidal antiinflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004;63:588-90.
11. Piekarek K, Israelsson LA. Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis 2008;23:1193-7.
12. Závada J, Lunt M, Davies R, et al. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Ann Rheum Dis 2014;73:252-5.
13. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:1-13.
14. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
15. van Vollenhoven RF, Keystone EC, Furie R, et al. Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials. Arthritis Rheum 2009;60:1613.
16. Yamamoto K, Goto H, Hirao K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 2015;42:1368-75.
17. Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015;44:381-8.
18. Myasoedova E, Matteson EL, Talley NJ, et al. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. J Rheumatol 2012;39:1355-62.
19. Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:1819-28.
20. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002;122:2011-25.
21. Siegmund B, Sennello JA, Jones-Carson J, et al. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut 2004;53:965-72.
22. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012;61:78-85.
23. Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?. Gut 2012;61:86-94.